Vanguard Capital Management
RLAY icon

Vanguard Capital Management’s Relay Therapeutics RLAY Stock Holding History

Vanguard Capital Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$168M Buy
8,964,423
+1,576,958
+21% +$22.9M ﹤0.01% 1253
2026
Q1 		$73.5M Buy
+7,387,465
New +$66.1M ﹤0.01% 1640

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Vanguard Capital Management's RLAY Position: Q2 2026 in Review

Vanguard Capital Management increased its Relay Therapeutics (RLAY) stake by 21% in Q2 2026, buying an estimated $22.9M and bringing the position to 8,964,423 shares worth $168M. The position accounts for ﹤0.01% of the portfolio, ranked #1253.

Vanguard Capital Management first reported a position in RLAY in Q1 2026 and has held it in 2 quarters since. 256 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Vanguard Capital Management held 8,964,423 shares of Relay Therapeutics worth $168M as of Q2 2026.
  • Vanguard Capital Management bought 1,576,958 Relay Therapeutics shares in Q2 2026, an estimated $22.9M.
  • Relay Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1253 holding.
  • Vanguard Capital Management first reported a position in Relay Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 256 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.